Literature DB >> 24145987

Latest biopsy approach for suspected metastases in patients with breast cancer.

Naoki Niikura1, Bruno C Odisio, Yutaka Tokuda, Fraser W Symmans, Gabriel N Hortobagyi, Naoto T Ueno.   

Abstract

Biopsy of suspected metastases in patients with breast cancer is recommended in the practice guidelines of the National Comprehensive Cancer Network, but not always performed in routine oncology practice, often because of the cost and invasiveness of the procedure. Biopsies can confirm the presence of metastatic disease, reveal unsuspected benign disease or second (non-breast) malignancies and confirm expression of biomarkers, all of which can aid the optimal management of the cancer. Image-guided biopsy has increased the accuracy and safety of the procedure. Here, we aim to provide a practical algorithm for deciding when to perform biopsy of suspected breast cancer metastases, in order to optimize clinical practice. We expect that future clinical trials and standard-of-care practice will increasingly obtain tissue from metastases to assess molecular differences (DNA, RNA, protein) between the primary tumour and metastases. Advances in targeted therapy for breast cancer will be highly dependent on the availability of metastatic tissue. In this article, we provide an up-to-date review of the current issues in biopsy of suspected metastases in patients with breast cancer, including technical details of biopsy, pathology review of biopsy specimens, and interpretation of biopsy findings.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24145987     DOI: 10.1038/nrclinonc.2013.182

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  103 in total

1.  Combining fine-needle aspiration and core biopsy under CT fluoroscopy guidance: a better way to treat patients with lung nodules?

Authors:  Takuji Yamagami; Shigeharu Iida; Takeharu Kato; Osamu Tanaka; Tsunehiko Nishimura
Journal:  AJR Am J Roentgenol       Date:  2003-03       Impact factor: 3.959

2.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

3.  Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.

Authors:  Takayuki Iwamoto; Daniel Booser; Vicente Valero; James L Murray; Kimberly Koenig; Francisco J Esteva; Naoto T Ueno; Jie Zhang; Weiwei Shi; Yuan Qi; Junji Matsuoka; Elliana J Yang; Gabriel N Hortobagyi; Christos Hatzis; W Fraser Symmans; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2012-01-30       Impact factor: 44.544

4.  Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.

Authors:  M Tanner; P Järvinen; J Isola
Journal:  Cancer Res       Date:  2001-07-15       Impact factor: 12.701

5.  Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.

Authors:  C Liedtke; K Broglio; S Moulder; L Hsu; S-W Kau; W F Symmans; C Albarracin; F Meric-Bernstam; W Woodward; R L Theriault; L Kiesel; G N Hortobagyi; L Pusztai; A M Gonzalez-Angulo
Journal:  Ann Oncol       Date:  2009-07-12       Impact factor: 32.976

6.  Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes.

Authors:  Elizabeth A Mittendorf; Yun Wu; Maurizio Scaltriti; Funda Meric-Bernstam; Kelly K Hunt; Shaheenah Dawood; Francisco J Esteva; Aman U Buzdar; Huiqin Chen; Sameena Eksambi; Gabriel N Hortobagyi; Jose Baselga; Ana M Gonzalez-Angulo
Journal:  Clin Cancer Res       Date:  2009-11-17       Impact factor: 12.531

7.  Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer.

Authors:  Judith Hurley; Philomena Doliny; Isildinha Reis; Orlando Silva; Carmen Gomez-Fernandez; Pedro Velez; Giovanni Pauletti; Jodeen E Powell; Mark D Pegram; Dennis J Slamon
Journal:  J Clin Oncol       Date:  2006-03-20       Impact factor: 44.544

Review 8.  Breast cancer seeding associated with core needle biopsies: a systematic review.

Authors:  Fabienne Liebens; Birgit Carly; Pino Cusumano; Martine Van Beveren; Barbara Beier; Maxime Fastrez; Serge Rozenberg
Journal:  Maturitas       Date:  2009-01-22       Impact factor: 4.342

9.  Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations.

Authors:  Krisztina Z Hanley; George G Birdsong; Cynthia Cohen; Momin T Siddiqui
Journal:  Cancer       Date:  2009-08-25       Impact factor: 6.860

10.  Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease.

Authors:  J Zidan; I Dashkovsky; C Stayerman; W Basher; C Cozacov; A Hadary
Journal:  Br J Cancer       Date:  2005-09-05       Impact factor: 7.640

View more
  2 in total

Review 1.  Using tumour phylogenetics to identify the roots of metastasis in humans.

Authors:  Kamila Naxerova; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2015-01-20       Impact factor: 66.675

2.  International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference.

Authors:  Naoto T Ueno; Jose Rodrigo Espinosa Fernandez; Massimo Cristofanilli; Beth Overmoyer; Dan Rea; Fedor Berdichevski; Mohamad El-Shinawi; Jennifer Bellon; Huong T Le-Petross; Anthony Lucci; Gildy Babiera; Sarah M DeSnyder; Mediget Teshome; Edward Chang; Bora Lim; Savitri Krishnamurthy; Michael C Stauder; Simrit Parmar; Mona M Mohamed; Angela Alexander; Vicente Valero; Wendy A Woodward
Journal:  J Cancer       Date:  2018-04-06       Impact factor: 4.207

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.